ScreenerHero

TBPH Theravance Biopharma, Inc. - Ordinary Shares

NAS · US · Healthcare · Biotechnology · theravance.com
17.03USD0.00%Mkt Cap: 884.18M $P/E: 16.38

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap884.18M USD
Enterprise Value535.09M USD
Revenue (TTM)104.31M USD
Gross Profit78.30M USD
Net Income (TTM)105.89M USD
Revenue/Share2.04 USD
Last Price17.03 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees90
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)16.38
P/E (Forward)13.36
PEG—
EV/EBITDA48.20
EV/Revenue5.13
P/S8.48
P/B3.05
EPS (TTM)1.04
EPS (Forward)1.27
52W Range
13.0850% of range21.03
52W High21.03 USD
52W Low13.08 USD
Profitability
Gross Margin75.06%
Oper. Margin8.89%
EBITDA Margin10.64%
Profit Margin98.54%
ROE35.69%
ROA21.81%
Growth
Revenue Growth-20.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF238.54M USD
CapEx (TTM)42.00K USD
FCF Margin5.08%
FCF Yield0.60%
Net Debt-349.09M USD
Net Debt/EBITDA-31.44
Balance Sheet
Debt/Equity0.14
Current Ratio13.54
Quick Ratio13.26
Book Value/Sh5.58 USD
Cash/Share7.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.67 USD
Upside (mean)+3.7%
Target Range17.00 USD – 19.00 USD
17.00+3.7% to mean19.00
# Analysts3
Ownership
Shares Out.51.92M
Float25.87M
Insiders4.61%
Institutions94.71%
Short Interest
Short Ratio4.5d
Short % Float5.18%
Short % Out.3.25%
Shares Short1.69M
Short (prev mo.)1.71M
Technical
SMA 5016.97 (+0.4%)
SMA 20017.16 (-0.8%)
Beta0.24
S&P 52W Chg15.78%
Avg Vol (30d)983.13K
Avg Vol (10d)1.90M
Technical Indicators
RSI (14)55.3
MACD0.0250
MACD Signal0.0328
MACD Hist.-0.0077
BB Upper17.09 USD
BB Middle17.03 USD
BB Lower16.97 USD
BB Width0.73%
ATR (14)0.0568 USD
Vol Ratio (20d)0.00x